ORA - Oxford University Research Archive

1 - 6 of 6

1

Conference

STRONTIUM RANELATE PREVENTS RADIOLOGICAL PROGRESSION IN PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS: A RESPONDERS ANALYSIS

Cooper, C, Berenbaum, F, Nash, P, et al.
2013-04-05

2

Conference

Prevention Of Radiological Progression In Patients With Primary Knee Osteoarthritis With Strontium Ranelate

Reginster, J-Y, Chapurlat, R, Berenbaum, F, et al.
2013-10-05

3

Conference item

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Nash, P, Coates, LC, Kivitz, AJ, et al.
2018-10-15

4

Conference item

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

conference abstract
Nash, P, Coates, LC, Kivitz, AJ, et al.
2018-06-12

5

Journal article

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Nash, P, Mease, PJ, Fleishaker, D, et al.
2020-11-16

6

Journal article

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study

Nash, P, Coates, LC, Fleishaker, D, et al.

TO TOP